DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Pierpont syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePierpont syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pierpont syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
TBL1X/Y related 1 (TBL1XR1) — TBL1XR1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet unxdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4LG9 · 2.28 Å · ligand UNKNOWN ATOM OR ION (UNX). Experimental structure, not a prediction.
What the evidence adds up to
Pierpont syndrome is defined by developmental delay, a characteristic facial appearance, hearing loss, and abnormal fat distribution in the distal limbs. A 2017 report of a male child with the syndrome identified the identical TBL1XR1 mutation [c.1337A>G; p.(Tyr446Cys)] previously described in six unrelated patients. That patient also had microphthalmia, pendular nystagmus, cryptorchidism, dermal sinus, and peripheral joint laxity — features not previously reported in Pierpont syndrome. The authors concluded that the syndrome is exclusively caused by that specific missense mutation.
A 2018 study challenged that exclusivity. Two patients with typical Pierpont-like features were found to carry different de novo heterozygous missense TBL1XR1 variants: p.Cys325Tyr and p.Tyr446His. The authors argued that patients with TBL1XR1 deletion or other loss-of-function variants do not share the same phenotype, suggesting a dominant-negative mechanism for the missense mutations. The functional consequences of the two new mutations were considered comparable to the recurrent p.Tyr446Cys change.
A 2011 collaborative study, before the genetic basis was known, described a series of patients with the condition. It noted distinctive shared facial characteristics, plantar fat pads, and other limb abnormalities. Some individuals with striking hand and foot findings but less characteristic facies were considered unlikely to have the same condition. High-resolution array CGH or SNP array in several possible patients did not identify an etiology at that time. The authors were uncertain whether Pierpont syndrome is a single entity.
No drug treatment or therapeutic trial for Pierpont syndrome has been reported in any of these studies. What is missing is any investigation of pharmacological intervention, any animal model for testing, and any systematic natural history study that could define endpoints for a future trial. The genetic mechanism — dominant-negative missense mutations in TBL1XR1 — suggests a target, but no drug has been proposed or tested. Patient stratification by specific mutation is now possible, but funding for preclinical work and trial design remains absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical Dysmorphology · 2017 · 20 citations
Pierpont syndrome: report of a new patient
AbstractPierpont syndrome (OMIM #602342) is a rare disorder characterized by developmental delay, characteristic facial gestalt, hearing loss, and abnormal fat distribution in the distal limbs. A specific mutation in TBL1XR1 [c.1337A>G; p.(Tyr446Cys)] has been described recently in six unrelated patients with Pierpont syndrome. We report on a male child with developmental delay, distinctive facial dysmorphic features, dystrophy, and abnormal fat distribution in the feet, in whom we identified the identical TBL1XR1 mutation. This patient also had additional clinical features including microphthalmia, pendular nystagmus, cryptorchidism, dermal sinus, and peripheral joint laxity, which had not been reported previously in association with Pierpont syndrome. This patient corroborates the assumption that Pierpont syndrome is exclusively caused by the specific TBL1XR1 missense mutation p.(Tyr446Cys) and the additional features broaden the phenotypic spectrum of this rare disorder.
American Journal of Medical Genetics Part A · 2018 · 18 citations
<i>TBL1XR1</i> mutations in Pierpont syndrome are not restricted to the recurrent p.Tyr446Cys mutation
AbstractPierpont syndrome is a rare and sporadic syndrome, including developmental delay, facial characteristics, and abnormal extremities. Recently, a recurrent de novo TBL1XR1 variant (c.1337A > G; p.Tyr446Cys) has been identified in eight patients by whole-exome sequencing. A dominant-negative effect of this mutation is strongly suspected, since patients with TBL1XR1 deletion and other variants predicting loss of function do not share the same phenotype. We report two patients with typical Pierpont-like syndrome features. Exome sequencing allowed identifying a de novo heterozygous missense TBL1XR1 variant in both patients, different from those already reported: p.Cys325Tyr and p.Tyr446His. The localization of these mutations and clinical features of Pierpont-like syndrome suggest that their functional consequences are comparable with the recurrent mutation previously described, and provided additional data to understand molecular mechanisms of TBL1XR1 anomalies.
American Journal of Medical Genetics Part A · 2011 · 16 citations · open access
Pierpont syndrome: A collaborative study
AbstractPierpont syndrome is a multiple congenital anomaly syndrome with learning disability first described in 1998. There are only three patients with Pierpont syndrome who have previously been published in the literature. Details of a series of patients with features of this condition were therefore obtained retrospectively to better characterize its key features. These patients were noted to have distinctive shared facial characteristics, in addition to plantar fat pads and other limb abnormalities. Further individuals with equally striking hand and foot findings were identified whose facies were less characteristic, and hence we considered them unlikely to be affected with the same condition. Despite several patients with possible Pierpont syndrome having had high-resolution array CGH or SNP array, the etiology of this phenotype remains unknown. Whilst it is as yet unclear whether it is a single entity, there appears to be a group of patients in whom Pierpont syndrome may be a recognizable condition, with typical facies, particularly when smiling, and characteristic hand and foot findings.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
